

Korea DPR Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Korea DPR					
2. Grant number: 17-PRK-32a-X / 18-PRK-32a-X / 19-PRK-32a-X / 20-PRK-32a-X					
3. Date of Decision Letter: 14 December 2017					
4. Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: Injection safety devices ¹					
6. Programme duration²: 2017-2020					
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)					
	2017	2018	2019	2020	Total ³
Programme Budget (US\$)	51,000	53,000	54,000	54,000	212,000
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴					
TOTAL injection safety devices to be purchased with Gavi funds in each year		2017	2018		
Number of AD syringes			1,167,400		
Number of re-constitution syringes					
Number of safety boxes			12,850		
Annual Amounts for injection safety devices for all Gavi vaccines (US\$)		51,000	53,000		
Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u>					
New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID, Routine		2018			
Number of AD syringes		0			
Number of re-constitution syringes		0			

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

Number of safety boxes	0
Annual Amounts for injection safety devices for Vaccine (US\$)	0
New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	2018
Number of AD syringes	1,167,400
Number of re-constitution syringes	
Number of safety boxes	12,850
Annual Amounts for injection safety devices for Vaccine (US\$)	53,000
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
10. Self-procurement: Not applicable	
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
14 December 2017